Daniel J. DeAngelo, MD, PhD, is the clinical director of the Adult Leukemia Program at Dana-Farber Cancer Institute (DFCI). He is also an associate professor in the Department of Medicine at Harvard Medical School and an attending physician at Brigham and Womens Hospital (BWH). Dr DeAngelo maintains a large academic clinical practice, which is responsible for the diagnosis and treatment of patients with acute and chronic leukemia, myelodysplasia, and other stem cell;hematopoietic disorders. His current research interests include novel immunotherapeutic approaches to the treatment of acute myelogenous leukemia and myelodysplasia, and he is currently developing leukemia tumor vaccines from patients with advanced myelodysplasia (AML). Dr DeAngelo is a member of the National Comprehensive Cancer Network and the World CML Registry Steering Committee for Novartis. He has been an invited lecturer to several national and international conferences and has won multiple teaching awards including the Medical Oncology Education Award and the Lee Nadler Extra Mile Award, both from DFCI. Dr DeAngelo received his BS from University of California at Berkeley. He graduated with an MS, MD, and PhD from the Albert Einstein College of Medicine at Yeshiva University. His residency was completed at Massachusetts General Hospital and he completed fellowships at both DFCI and BWH.